Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. The definitive merger agreement was announced February 5, 2015. Pfizer has agreed to acquire Hospira for a total enterprise value of approximately $17 Billion in cash.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
